CTOs on the Move

AccuraGen Holdings

www.accuragen.com

 
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.accuragen.com
  • 1455 Adams Dr Suite 1015
    Menlo Park, CA USA 94025
  • Phone: 650.618.5028

Executives

Name Title Contact Details

Funding

AccuraGen Holdings raised $40M on 06/01/2016

Similar Companies

Future Family

Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.

Vital Probes Inc

Vital Probes Inc is a Jermyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthsouth Rehabilitation Hospital

Healthsouth Rehabilitation Hospital is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.